Hypercholesterolaemia Clinical Trial
Official title:
Non-interventional Study to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors in Bosnia and Herzegovina
This study is non-interventional study of patients who are treated with any HMGCoA reductase inhibitors (rosuvastatin, simvastatin,atorvastatin and fluvastatin) available in Bosnia and Herzegovina for at least 6 months. Data collection for each patient will take place at a single visit. The investigators will complete Case Report Form (CRF) with patient's demographic, the presence of the factors for high cardiovascular risk, current treatment, cholesterol value as well as with further treatment decision.
Non-interventional study to assess reaching of cholesterol target values in patients treated with HMG-CoA reductase inhibitors in Bosnia and Herzegovina ;
Observational Model: Cohort, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01935674 -
Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels
|
Phase 4 | |
Completed |
NCT02890992 -
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
|
Phase 2 | |
Completed |
NCT00653835 -
Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)
|
Phase 4 | |
Recruiting |
NCT06008756 -
MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
|
Phase 3 | |
Completed |
NCT02585778 -
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
|
Phase 3 | |
Completed |
NCT00329173 -
PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.
|
Phase 3 | |
Completed |
NCT04169386 -
A Study of PCSK9 Inhibitor AK102 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02770131 -
Chart Review of Repatha® in Subjects With Hyperlipidaemia
|
||
Completed |
NCT03510884 -
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
|
Phase 3 | |
Recruiting |
NCT06275724 -
Specified Drug-use Survey of Leqvio for s.c. Injection.
|
||
Completed |
NCT03415178 -
Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
|
Phase 3 | |
Completed |
NCT01779687 -
Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.
|
Phase 1 | |
Completed |
NCT01617655 -
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)
|
Phase 3 | |
Completed |
NCT00328523 -
TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)
|
Phase 3 | |
Completed |
NCT05934292 -
MK-0616 (Oral PCSK9 Inhibitor) Renal Impairment Study 2 (MK-0616-020)
|
Phase 1 | |
Completed |
NCT01257971 -
Non-interventional Study (NIS) to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors
|
N/A | |
Completed |
NCT00163163 -
Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women
|
Phase 3 | |
Completed |
NCT01597700 -
Acotral® Versus Zetia® Ezetimibe Bioequivalance Study.
|
Phase 1 | |
Terminated |
NCT02906124 -
Study to Evaluate the Safety of Repatha® in Pregnancy
|
||
Completed |
NCT01711749 -
Rosuvastatin Calcium Bioequivalence Study - Fast
|
Phase 1 |